OrbiMed Genesis GP LLC
CIK 0001808744 Name as filed on the most recent filing
Filed as OrbiMed Genesis GP LLC (70)
219 transaction lines · from 70 filings · filed 2020-04-13 to 2026-08-11 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Braveheart Bio, Inc. 1 filings
- ISSUER Enliven Therapeutics, Inc. 3 filings
- ISSUER Q32 Bio Inc. 1 filings
- ISSUER Prelude Therapeutics Inc 1 filings
- ISSUER Adicet Bio, Inc. 4 filings
- ISSUER Shattuck Labs, Inc. 1 filings
- ISSUER Compass Therapeutics, Inc. 5 filings
- ISSUER Edgewise Therapeutics, Inc. 5 filings
- ISSUER Disc Medicine, Inc. 8 filings
- ISSUER MBX Biosciences, Inc. 2 filings
- ISSUER scPharmaceuticals Inc. 3 filings
- ISSUER Keros Therapeutics, Inc. 2 filings
- ISSUER Terns Pharmaceuticals, Inc. 3 filings
- ISSUER Alpine Immune Sciences, Inc. 2 filings
- ISSUER PMV Pharmaceuticals, Inc. 4 filings
- ISSUER Galecto, Inc. 8 filings
- ISSUER Theseus Pharmaceuticals, Inc. 5 filings
- ISSUER Kinnate Biopharma Inc. 3 filings
- ISSUER Ikena Oncology, Inc. 3 filings
- ISSUER Janux Therapeutics, Inc. 4 filings
- ISSUER Decibel Therapeutics, Inc. 1 filings
- ISSUER LogicBio Therapeutics, Inc. 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2025-02-18 |
MBX Biosciences, Inc. MBX |
P, Open-market purchase | 94,100 acquired | 10.84 | 1,020,044.00 | Form 4, filing 0000947871-25-000199 | |
| 2025-02-18 |
MBX Biosciences, Inc. MBX |
P, Open-market purchase | 49,070 acquired | 10.84 | 531,918.80 | Form 4, filing 0000947871-25-000199 | |
| 2025-02-14 |
MBX Biosciences, Inc. MBX |
P, Open-market purchase | 29,540 acquired | 9.85 | 290,969.00 | Form 4, filing 0000947871-25-000199 | |
| 2025-02-14 |
MBX Biosciences, Inc. MBX |
P, Open-market purchase | 17,962 acquired | 9.90 | 177,823.80 | Form 4, filing 0000947871-25-000199 | |
| 2024-09-16 |
MBX Biosciences, Inc. MBX |
P, Open-market purchase | 500,000 acquired | 16.00 | 8,000,000.00 | Form 4, filing 0000950170-24-107538 | |
| 2024-09-16 |
MBX Biosciences, Inc. MBX |
P, Open-market purchase | 250,000 acquired | 16.00 | 4,000,000.00 | Form 4, filing 0000950170-24-107538 | |
| 2024-08-13 |
Keros Therapeutics, Inc. KROS |
S, Open-market sale | 220,600 disposed | 44.01 | 9,708,606.00 | Form 4, filing 0000947871-24-000702 | |
| 2024-08-13 |
Keros Therapeutics, Inc. KROS |
S, Open-market sale | 29,400 disposed | 44.01 | 1,293,894.00 | Form 4, filing 0000947871-24-000702 | |
| 2024-08-13 |
scPharmaceuticals Inc. SCPH |
P, Open-market purchase | 478,342 acquired | 4.00 | 1,913,368.00 | Form 4, filing 0000947871-24-000701 | |
| 2024-08-13 |
scPharmaceuticals Inc. SCPH |
P, Open-market purchase | 21,658 acquired | 4.00 | 86,632.00 | Form 4, filing 0000947871-24-000701 | |
| 2024-07-16 |
Terns Pharmaceuticals, Inc. TERN |
S, Open-market sale | 4,009 disposed | 10.00 | 40,090.00 | Form 4, filing 0000947871-24-000627 | |
| 2024-07-16 |
Terns Pharmaceuticals, Inc. TERN |
S, Open-market sale | 623 disposed | 10.00 | 6,230.00 | Form 4, filing 0000947871-24-000627 | |
| 2024-07-16 |
Terns Pharmaceuticals, Inc. TERN |
S, Open-market sale | 556 disposed | 10.00 | 5,560.00 | Form 4, filing 0000947871-24-000627 | |
| 2024-07-15 |
Terns Pharmaceuticals, Inc. TERN |
S, Open-market sale | 39,433 disposed | 10.00 | 394,330.00 | Form 4, filing 0000947871-24-000627 | |
| 2024-07-15 |
Terns Pharmaceuticals, Inc. TERN |
S, Open-market sale | 6,142 disposed | 10.00 | 61,420.00 | Form 4, filing 0000947871-24-000627 | |
| 2024-07-15 |
Terns Pharmaceuticals, Inc. TERN |
S, Open-market sale | 5,401 disposed | 10.00 | 54,010.00 | Form 4, filing 0000947871-24-000627 | |
| 2024-06-17 |
Disc Medicine, Inc. IRON |
P, Open-market purchase | 43,944 acquired | 36.00 | 1,581,984.00 | Form 4, filing 0000947871-24-000573 | |
| 2024-06-17 |
Disc Medicine, Inc. IRON |
P, Open-market purchase | 28,404 acquired | 36.00 | 1,022,544.00 | Form 4, filing 0000947871-24-000573 | |
| 2024-06-17 |
Disc Medicine, Inc. IRON |
P, Open-market purchase | 10,986 acquired | 36.00 | 395,496.00 | Form 4, filing 0000947871-24-000573 | |
| 2024-05-16 |
Enliven Therapeutics, Inc. ELVN |
S, Open-market sale | 1,000,000 disposed | 22.14 | 22,140,000.00 | Form 4, filing 0000947871-24-000500 | |
| 2024-05-16 |
Enliven Therapeutics, Inc. ELVN |
S, Open-market sale | 33,300 disposed | 22.14 | 737,262.00 | Form 4, filing 0000947871-24-000500 | |
| 2024-01-25 |
Adicet Bio, Inc. ACET |
P, Open-market purchase | 1,841,100 acquired | 2.40 | 4,418,640.00 | Form 4, filing 0000950170-24-008053 | |
| 2024-01-25 |
Adicet Bio, Inc. ACET |
P, Open-market purchase | 1,041,700 acquired | 2.40 | 2,500,080.00 | Form 4, filing 0000950170-24-008053 | |
| 2024-01-25 |
Adicet Bio, Inc. ACET |
P, Open-market purchase | 242,200 acquired | 2.40 | 581,280.00 | Form 4, filing 0000950170-24-008053 | |
| 2024-01-23 |
Edgewise Therapeutics, Inc. EWTX |
P, Open-market purchase | 454,545 acquired | 11.00 | 4,999,995.00 | Form 4, filing 0000947871-24-000069 | |
| 2023-12-28 |
Alpine Immune Sciences, Inc. ALPN |
S, Open-market sale | 1,195,683 disposed | 18.32 | 21,904,912.56 | Form 4, filing 0000947871-23-001189 | |
| 2023-12-28 |
Alpine Immune Sciences, Inc. ALPN |
S, Open-market sale | 139,166 disposed | 18.32 | 2,549,521.12 | Form 4, filing 0000947871-23-001189 | |
| 2023-12-28 |
Alpine Immune Sciences, Inc. ALPN |
S, Open-market sale | 26,872 disposed | 19.82 | 532,603.04 | Form 4, filing 0000947871-23-001189 | |
| 2023-12-28 |
Alpine Immune Sciences, Inc. ALPN |
S, Open-market sale | 3,128 disposed | 19.82 | 61,996.96 | Form 4, filing 0000947871-23-001189 | |
| 2023-12-27 |
Alpine Immune Sciences, Inc. ALPN |
S, Open-market sale | 162,576 disposed | 19.96 | 3,245,016.96 | Form 4, filing 0000947871-23-001189 | |
| 2023-12-27 |
Alpine Immune Sciences, Inc. ALPN |
S, Open-market sale | 18,922 disposed | 19.96 | 377,683.12 | Form 4, filing 0000947871-23-001189 | |
| 2023-12-18 |
Disc Medicine, Inc. IRON |
S, Open-market sale | 1,724 disposed | 59.24 | 102,129.76 | Form 4, filing 0000947871-23-001168 | |
| 2023-12-14 |
Disc Medicine, Inc. IRON |
S, Open-market sale | 100 disposed | 57.73 | 5,773.00 | Form 4, filing 0000947871-23-001148 | |
| 2023-12-14 |
Disc Medicine, Inc. IRON |
S, Open-market sale | 100 disposed | 57.73 | 5,773.00 | Form 4, filing 0000947871-23-001148 | |
| 2023-12-14 |
Disc Medicine, Inc. IRON |
S, Open-market sale | 228,500 disposed | 56.75 | 12,967,375.00 | Form 4, filing 0000947871-23-001154 | |
| 2023-12-14 |
Disc Medicine, Inc. IRON |
S, Open-market sale | 147,600 disposed | 56.75 | 8,376,300.00 | Form 4, filing 0000947871-23-001154 | |
| 2023-12-14 |
Disc Medicine, Inc. IRON |
S, Open-market sale | 57,100 disposed | 56.75 | 3,240,425.00 | Form 4, filing 0000947871-23-001154 | |
| 2023-12-13 |
Disc Medicine, Inc. IRON |
S, Open-market sale | 56,200 disposed | 58.56 | 3,291,072.00 | Form 4, filing 0000947871-23-001148 | |
| 2023-12-13 |
Disc Medicine, Inc. IRON |
S, Open-market sale | 36,400 disposed | 58.56 | 2,131,584.00 | Form 4, filing 0000947871-23-001148 | |
| 2023-12-13 |
Disc Medicine, Inc. IRON |
S, Open-market sale | 14,100 disposed | 58.56 | 825,696.00 | Form 4, filing 0000947871-23-001148 | |
| 2023-12-12 |
Disc Medicine, Inc. IRON |
S, Open-market sale | 14,400 disposed | 60.16 | 866,304.00 | Form 4, filing 0000947871-23-001148 | |
| 2023-12-12 |
Disc Medicine, Inc. IRON |
S, Open-market sale | 9,300 disposed | 60.16 | 559,488.00 | Form 4, filing 0000947871-23-001148 | |
| 2023-12-12 |
Disc Medicine, Inc. IRON |
S, Open-market sale | 3,600 disposed | 60.16 | 216,576.00 | Form 4, filing 0000947871-23-001148 | |
| 2023-11-22 |
PMV Pharmaceuticals, Inc. PMVP |
S, Open-market sale | 87,786 disposed | 2.23 | 195,762.78 | Form 4, filing 0000947871-23-001104 | |
| 2023-08-15 |
Galecto, Inc. GLTO |
S, Open-market sale | 535,534 disposed | 0.75 | 401,650.50 | Form 4, filing 0000947871-23-000873 | |
| 2023-08-15 |
Galecto, Inc. GLTO |
S, Open-market sale | 248,819 disposed | 0.75 | 186,614.25 | Form 4, filing 0000947871-23-000873 | |
| 2023-08-15 |
Galecto, Inc. GLTO |
S, Open-market sale | 38,327 disposed | 0.75 | 28,745.25 | Form 4, filing 0000947871-23-000873 | |
| 2023-07-31 |
Galecto, Inc. GLTO |
S, Open-market sale | 153,078 disposed | 3.00 | 459,234.00 | Form 4, filing 0000947871-23-000809 | |
| 2023-07-31 |
Galecto, Inc. GLTO |
S, Open-market sale | 29,700 disposed | 3.00 | 89,100.00 | Form 4, filing 0000947871-23-000809 | |
| 2023-07-31 |
Galecto, Inc. GLTO |
S, Open-market sale | 26,622 disposed | 3.00 | 79,866.00 | Form 4, filing 0000947871-23-000809 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. OrbiMed Genesis GP LLC, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001808744
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6